Peptide-based approaches to treat lupus and other autoimmune diseases.
After a long period where the potential of therapeutic peptides was let into oblivion and even dismissed, there is a revival of interest in peptides as potential drug candidates. Novel strategies for limiting metabolism and improve their bioavailability, and alternative routes of administration have emerged. This resulted in a large number of peptide-based drugs that are now being marketed in different indications. Regarding autoimmunity, successful data have been reported in numerous mouse models of autoimmune inflammation, yet relatively few clinical trials based on synthetic peptides are currently underway. This review reports on peptides that show much promises in appropriate mouse models of autoimmunity and describes in more detail clinical trials based on peptides for treating autoimmune patients. A particular emphasis is given to the 21-mer peptide P140/Lupuzor that has completed successfully phase I, phase IIa and phase IIb clinical trials for systemic lupus erythematosus.
CNRS, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France.
Nicolas
N
Schall
Nicolas
N
Page
Christophe
C
Macri
Olivier
O
Chaloin
Jean-Paul
JP
Briand
Sylviane
S
Muller
D000595:Amino Acid Sequence; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000276:immunology; D015551:Autoimmunity / Q000187:drug effects; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004333:Drug Administration Routes; D004334:Drug Administration Schedule; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality; D051379:Mice; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000008:administration & dosage / Q000493:pharmacokinetics*; D015996:Survival Rate
D007155:Immunologic Factors; D010446:Peptide Fragments; C535176:spliceosomal peptide P140